Bioharmony Therapeutics, Inc. Company Profile
Bioharmony Therapeutics, Inc. is an emerging biopharmaceutical company
focused on the discovery and development of first-in-class lysin-based
antimicrobial therapeutics for patients with multi-drug resistant
Gram-negative bacterial infections. In addition to the Acinetobacter
lysin, Bioharmonyâs portfolio includes a proprietary line-up of lysins
for the treatment for pneumonia, skin, urinary tract and bloodstream
infections caused by Gram-negative bacterial infections such as E.coli,
Klebsiella and others.
News Articles
Bioharmony, Boehringer to advance bacteriophage lysin therapeutics to treat MDR bacterial infections
Bioharmony licensed this technology from the Rockefeller University. The discoveries are from the laboratory of Vincent A. Fischetti, Ph.D., a faculty member at The Rockefeller University. Recently, t...
Bioharmony licensed this technology from the Rockefeller University. The discoveries are from the laboratory of Vincent A. Fischetti, Ph.D., a faculty member at The Rockefeller University. Recently, t...
Boehringer and Bioharmony partner to develop therapies for bacterial infections
Bioharmony Therapeutics Inc. and Boehringer Ingelheim GMBH agreed to collaborate on the development of bacteriophage lysins for the treatment of multidrug-resistant (MDR) Acinetobacter infections.
Bioharmony licensed this technology from the Rockefeller University. The discoveries are from the laboratory of Vincent A. Fischetti, Ph.D., a faculty member at The Rockefeller University. Recently, t...
Collaboration aims to develop first-in-class therapies for treatment resistant hospital acquired bacterial infections caused by Acinetobacter baumannii ...
Bioharmony, Boehringer partner to develop antimicrobials
M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin
Nabriva Therapeutics has completed the acquisition of Zavante Therapeutics for $97.5m. The acquisition will add the target company’s CONTEPO™ drug, which...Read More... The post M&As this we...
Roche’s Genentech agrees to buy Jecure Therapeutics
Based in San Diego of California, Jecure Therapeutics is engaged in the discovery of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics president and CE...
Drugs and Medications
Aldex [Pernix Therapeutics, LLC]
ALDEX GS™ Tablets
Kynamro [Kastle Therapeutics, LLC]
NA
Aldex [Pernix Therapeutics, LLC]
ALDEX GS DMTablets
Pro-den rx [Zila Therapeutics, Inc.]
Pro-Den Rx
Pro-den rx [Zila Therapeutics, Inc.]
Pro-Den Rx
PubMed Articles
Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...
RNA-targeted therapeutics for lipid disorders.
To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.
Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...
Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro.
In recent times, co-delivery of therapeutics has emerged as a promising strategy for treating dreadful diseases such as cancer.
Clinical Trials
Impact of Ibis on Patients With Advanced COPD
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...
HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia
Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...
This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...
Companies
Bioharmony Therapeutics, Inc. is an emerging biopharmaceutical company focused on the discovery and development of first-in-class lysin-based antimicrobial therapeutics for patien...
Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...
Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...
Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...
Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics⢠solutions to benefit people with unmet medical needs through cognitive and neurobehavi...
More Information about "Bioharmony Therapeutics, Inc." on BioPortfolio
We have published hundreds of Bioharmony Therapeutics, Inc. news stories on BioPortfolio along with dozens of Bioharmony Therapeutics, Inc. Clinical Trials and PubMed Articles about Bioharmony Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bioharmony Therapeutics, Inc. Companies in our database. You can also find out about relevant Bioharmony Therapeutics, Inc. Drugs and Medications on this site too.
